Top Page
Telix Pharmaceuticals
(Sydney:TLX)
Telix Pharmaceuticals (TLX) vs. iShares MSCI Australia ETF (EWA)
Telix Pharmaceuticals Business Overview & Revenue Model
Telix Pharmaceuticals Earnings Call Summary
Telix Pharmaceuticals Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 783.21M | 502.55M | 160.10M | 7.60M | 5.21M |
| Gross Profit | 509.68M | 314.39M | 29.34M | -29.77M | -16.88M |
| EBITDA | 92.55M | 22.97M | -92.84M | -70.07M | -44.94M |
| Net Income | 49.92M | 5.21M | -104.08M | -80.51M | -44.89M |
Balance Sheet | |||||
| Total Assets | 1.52B | 398.30M | 260.59M | 109.81M | 164.44M |
| Cash, Cash Equivalents and Short-Term Investments | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M |
| Total Debt | 581.45M | 17.45M | 10.45M | 2.54M | 2.21M |
| Total Liabilities | 948.22M | 249.39M | 178.44M | 106.17M | 84.44M |
| Stockholders Equity | 568.21M | 148.91M | 80.01M | 2.16M | 79.02M |
Cash Flow | |||||
| Free Cash Flow | 9.00M | 13.09M | -77.83M | -60.67M | 1.64M |
| Operating Cash Flow | 43.03M | 23.88M | -63.97M | -59.33M | 1.96M |
| Investing Cash Flow | -135.17M | -25.49M | -17.00M | -2.73M | -1.09M |
| Financing Cash Flow | 638.92M | 10.19M | 174.96M | 2.85M | 34.12M |
Telix Pharmaceuticals Technical Analysis
Telix Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.86B | 13.35 | 51.39% | ― | -8.06% | -10.13% | |
77 Outperform | $544.34M | 14.39 | 19.93% | 0.46% | 12.74% | 27.56% | |
71 Outperform | $8.13B | 162.78 | 14.52% | ― | 55.85% | 893.42% | |
56 Neutral | AU$35.43M | ― | -36.95% | ― | ― | 11.11% | |
52 Neutral | $7.47B | -0.04 | -63.86% | 2.34% | 16.17% | 0.25% | |
50 Neutral | $365.10M | ― | -31.16% | ― | ― | 14.47% | |
43 Neutral | $2.21B | ― | -21.31% | ― | ― | ― |
Telix Pharmaceuticals Corporate Events
Telix Pharmaceuticals announced that its next-generation PSMA PET imaging agent, Gozellix, has been granted a permanent HCPCS code by the U.S. Centers for Medicare & Medicaid Services, effective from October 1, 2025. This milestone supports provider billing and reimbursement, facilitating clinical adoption and expanded access to PSMA PET imaging for prostate cancer patients in the U.S., and marks an important step in Telix’s mission to improve access to precision medicine imaging.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited announced the cessation of certain securities, specifically 67,000 share rights and 436,190 share appreciation rights, due to the lapse of conditional rights that were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational and financial strategies.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the quotation of 133,825 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code TLX. This move is part of the company’s strategy to enhance its capital structure and support its growth initiatives, potentially strengthening its market position and providing new opportunities for stakeholders.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has announced a change in the director’s interest, specifically for Dr. Christian Behrenbruch, who has acquired 166,483 Performance Share Appreciation Rights (PSARs) and 2,595 Deferred Share Rights (SRs) as part of his remuneration package. This change reflects the company’s commitment to aligning executive compensation with performance goals, potentially impacting the company’s operational focus and stakeholder interests by incentivizing leadership to achieve significant revenue milestones.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited is hosting an Investor Day event in New York City, which will be a hybrid event allowing both in-person and virtual participation. This event is significant for stakeholders as it provides an opportunity for institutional investors and analysts to engage with the company, potentially impacting Telix’s market positioning and investor relations.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has announced the issuance of 15,000 ordinary fully paid securities, effective May 30, 2025. This move reflects the company’s ongoing efforts to enhance its capital structure and support its strategic initiatives in the biotechnology sector, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the issuance of 139,741 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code TLX. This move is part of the company’s strategy to enhance its capital structure and support its ongoing operations, potentially strengthening its position in the biotechnology sector and providing value to its stakeholders.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited announced the issuance of new unquoted equity securities as part of an employee incentive scheme. The issuance includes Deferred Share Rights for both US and ex-US employees and Performance Share Appreciation Rights for US employees, reflecting the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$36.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited announced the issuance of 1,541,188 share appreciation rights as part of an employee incentive scheme. This move is part of the company’s strategy to incentivize and retain its workforce, potentially impacting its operational efficiency and market positioning positively.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited announced the cessation of Harry Kevin McCann as a director effective May 21, 2025. McCann held indirect interests in the company through Monjoy Pty Limited and Cottesloe Pty Limited, with a total of 1,120,000 fully paid ordinary shares. This change in the board may impact the company’s governance structure and could have implications for its strategic direction.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals announced that all resolutions proposed at its Annual General Meeting were successfully passed by shareholders. This outcome reflects shareholder confidence and supports Telix’s strategic direction in the biopharmaceutical industry, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals announced the approval of its first-generation PSMA-PET imaging product, Illuccix®, and its osteomyelitis imaging agent, Scintimun®, in multiple countries. These approvals enhance Telix’s market presence and demonstrate its commitment to advancing medical imaging technologies. The company also highlighted its miniaturized surgical gamma probe, SENSEI®, which is registered for use in the U.S. and Europe, further solidifying its position in the medical imaging sector.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited held its Annual General Meeting where the Chairman and CEO addressed shareholders. The company continues to expand its product approvals globally, with Illuccix® and Gozellix® receiving approvals from various international health agencies. This expansion strengthens Telix’s market position in the biopharmaceutical industry, potentially enhancing its operational capabilities and stakeholder value.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited announced the release of 684,437 ordinary shares from voluntary escrow, which were initially issued to ImaginAb Inc. as part of an asset acquisition. This release, scheduled for May 29, 2025, is in accordance with ASX Listing Rule 3.10A and may impact the company’s operations by increasing share liquidity. The move reflects Telix’s ongoing strategic efforts to enhance its market positioning and could have implications for stakeholders by potentially influencing share value and investor confidence.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the quotation of 139,383 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective May 12, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide value to its stakeholders by expanding its capital base.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the issuance of new ordinary fully paid securities, totaling 210,000 shares, on two separate dates in May 2025. This move is part of the company’s strategy to manage its equity and potentially strengthen its financial position, which may have implications for its market performance and stakeholder interests.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the cessation of 135,000 share rights under the ASX security code TLXAP, effective May 16, 2025. This announcement may impact the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s issued securities.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the issuance of 135,000 unquoted share rights under an employee incentive scheme. This move is part of the company’s strategy to align employee interests with corporate goals, potentially enhancing productivity and commitment, which may positively impact Telix’s market position and stakeholder value.
Telix Pharmaceuticals Limited has issued 91,168 fully paid ordinary shares following the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This move, executed without disclosure under Part 6D.2 of the Corporations Act, signifies Telix’s strategic expansion in the radio-guided surgery market, potentially enhancing its industry positioning and stakeholder value.
Telix Pharmaceuticals Limited has announced the quotation of 91,168 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 6, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve its market position, offering stakeholders an opportunity to engage with the company’s growth and development in the biotech sector.
Telix Pharmaceuticals announced the resignation of Anne Whitaker from its board due to personal and family reasons, effective immediately. This resignation impacts the upcoming Annual General Meeting as her nomination for election has been withdrawn, but it does not affect the validity of proxy forms for the meeting. The company expressed regret over her departure and extended best wishes for her future endeavors.
Telix Pharmaceuticals Limited has announced the release of 2,427,636 ordinary shares from voluntary escrow, which were initially issued to QSAM Biosciences Inc. shareholders as part of Telix’s acquisition of QSAM. This release, scheduled for May 3, 2025, is in accordance with ASX Listing Rule 3.10A and marks a significant step in the integration process following the acquisition. The release of these shares is expected to impact Telix’s market operations by potentially increasing the liquidity of its shares and enhancing shareholder value.
Telix Pharmaceuticals Ltd. reported a significant 62% year-over-year increase in Q1 2025 revenue, reaching $186 million, driven by strong sales of Illuccix® and contributions from the recent acquisition of RLS Radiopharmacies. The company reaffirmed its FY 2025 revenue guidance and highlighted strategic expansions, including new market approvals and acquisitions, which are expected to enhance its global footprint and product offerings. The launch of Gozellix® in the U.S. and advancements in its therapeutic pipeline, such as the development of a new generator technology for lead-212, underscore Telix’s commitment to innovation and growth in the radiopharmaceutical sector.